Given that the KIF20A inhibitor effectively targets BCSCs (Figure 5), while conventional chemotherapy such as carboplatin efficiently debulks the bulk tumor cells, we evaluated the therapeutic efficacy of combining carboplatin with paprotrain in vivo. Here, KIF20A is linked to neoplasm.